Biolevate
AI platform for life sciences to scale trusted, auditable AI collaboration across regulated operations.
Website: https://www.biolevate.com/
Cover Block
Open sources
| Field | Value |
|---|---|
| Name | Biolevate |
| Tagline | AI platform for life sciences to scale trusted, auditable AI collaboration across regulated operations. [Biolevate, retrieved 2026] |
| Headquarters | Paris, France [TechCrunch, November 2024] |
| Founded | 2023 [Vestbee, November 2024] |
| Stage | Series A [Sesamers, September 2026] |
| Business Model | SaaS |
| Industry | Healthtech |
| Technology | AI / Machine Learning |
| Geography | Western Europe |
| Growth Profile | Venture Scale |
| Founding Team | Co-Founders (2) [Vestbee, November 2024] |
| Funding Label | Series A |
| Total Disclosed Funding | $38,640,000, arithmetic sum of disclosed rounds (estimated) from $6,440,000 seed and $32,200,000 Series A [TechCrunch, November 2024] [Sesamers, September 2026] |
Links
Open sources
- Website: https://www.biolevate.com/
- GitHub: https://github.com/biolevate
What an Investor Needs First
PUBLIC Biolevate is building an AI platform for life sciences that turns scientific and regulatory knowledge into auditable workflows, and it merits attention now because the company has moved from an initial medical-writing wedge to reported production use across more than ten enterprise customers while closing a €30 million Series A in September 2026 [TechCrunch, November 2024] [The Next Web, September 2026] [FrenchWeb, September 2026]. The core point is not generic automation, but traceable automation in regulated environments, with outputs linked to supporting evidence and subject to human sign-off, a positioning that fits the procurement logic of pharmaceutical and other regulated buyers better than fully autonomous claims do [The Next Web, September 2026] [Biolevate Careers, September 2026].
The company was founded in Paris in 2023, with reporting tying the launch to co-founders Joël Belafa and Nathan Chen, and later materials identifying a broader founding team that includes Nathan Di C., Antoine de Torcy, and Anas Laaroussi [Vestbee, November 2024] [LinkedIn, retrieved 2026]. Its first product, ELISE, was described as using natural-language processing and visual document reading to extract and structure unstructured scientific, healthcare, and regulatory information for medical writers and compliance-heavy document workflows [TechCrunch, November 2024].
Team quality is one reason the company has been able to widen that initial wedge. Coverage describes the founders and broader founding team as former Dataiku engineers and AI researchers, while LinkedIn materials identify Belafa as CEO, Di C. as COO, de Torcy as Chief AI Officer, and Laaroussi as CTO [The Next Web, September 2026] [LinkedIn, retrieved 2026]. That background does not prove commercial durability, but it does help explain the product's emphasis on governed workflows, document intelligence, and evidence traceability in a category where technical credibility matters [The Next Web, September 2026] [FinancialContent, September 2026].
On capital formation, Biolevate has disclosed €6 million of seed financing led by EQT Ventures in November 2024 and a €30 million Series A announced in September 2026, with RAISE France and Orange Ventures named as leads or co-leads across coverage and participation from MSD Global Health Innovation Fund, Station F, and EQT Ventures [TechCrunch, November 2024] [Biolevate, September 2026] [Tech.eu, September 2026]. The business model is SaaS, and the next 12 to 18 months will likely turn on whether Biolevate can translate regulated-workflow credibility into broader deployment depth, especially as it expands beyond Europe with a newly announced Boston office and a wider life-sciences platform narrative [The Next Web, September 2026] [Biolevate, September 2026].
Partially corroborated -- Built primarily from TechCrunch, The Next Web, Tech.eu, Vestbee, FrenchWeb, LinkedIn, and company materials; key funding and product claims are corroborated, but several scope and traction details remain partly company-sourced.
Taxonomy Snapshot
| Axis | Value |
|---|---|
| Stage | Series A |
| Business Model | SaaS |
| Industry / Vertical | Healthtech |
| Technology Type | AI / Machine Learning |
| Geography | Western Europe |
| Growth Profile | Venture Scale |
| Founding Team | Co-Founders (2) |
| Funding | Series A, total disclosed ~€36 million |
Inside the Company
PUBLIC
Biolevate entered the public record in 2024 as a Paris-based life sciences software company built around a narrow but commercially legible problem: regulated teams still work through large volumes of scientific and compliance documentation that do not tolerate casual automation [Biolevate, retrieved 2026]. The company says it was founded in 2023 and is headquartered in Paris, France, with its early positioning centered on turning scientific and regulatory knowledge into auditable workflows for pharmaceutical, biotech, medical-device, and other regulated organizations [Biolevate, retrieved 2026].
The milestone sequence is short enough to read cleanly. Biolevate first surfaced broadly with a seed financing in November 2024, when TechCrunch reported a €6 million round led by EQT Ventures and described the product focus as medical-writing and regulatory-document automation through its ELISE platform [TechCrunch, November 2024]. In September 2026, the company announced a €30 million Series A, stating that the platform had expanded its scope across the life sciences value chain and that the business was opening a Boston office alongside the raise [Biolevate, September 2026].
A few details remain uneven in public materials, which is common at this stage. Founder references in coverage consistently center on Joël Belafa and Nathan Chen, while company and LinkedIn footprints also surface a broader founding leadership bench that includes Nathan Di C., Antoine de Torcy, and Anas Laaroussi [LinkedIn, retrieved 2026]. No legal entity name is confirmed in the cited company materials used for this section, so the overview is best read as an operating-company summary rather than a full corporate-record abstract [Biolevate, retrieved 2026].
Partially corroborated -- Confirmed primarily by the company website, with chronology anchored by TechCrunch financing coverage.
Under the Hood
Reported and inferred
Biolevate’s product story is clearest at the workflow layer, not the model layer. Public reporting shows the company started with ELISE, a system for medical-writing and regulatory-document automation that uses natural-language processing and visual document reading to extract and structure unstructured scientific, healthcare, and regulatory information, with the medical writer as the initial target user [TechCrunch, November 2024]. By 2026, the company was positioning the platform more broadly as an enterprise AI knowledge platform for life sciences, aimed at turning scientific and regulatory knowledge into auditable workflows across regulated operations [Biolevate, September 2026] [Biolevate Careers, September 2026].
The consistent theme across sources is control and traceability. Biolevate and third-party coverage describe outputs that are linked to supporting evidence and subject to human sign-off, with an emphasis on auditability and human validation rather than fully autonomous decision-making [Biolevate Careers, September 2026] [The Next Web, September 2026]. Public materials also describe capabilities such as metadata extraction, collaborative document editing with version control, integration of internal and external research, and automation of regulatory monitoring, although some of those claims come directly from the company and should be treated as positioning rather than independently verified usage evidence [The AI Insider, November 2024] [Biolevate, retrieved 2026].
A few technical details are specific enough to matter. A public GitHub description says ELISE connects to document-storage backends including S3, Azure, GCS, SharePoint, SFTP, and local repositories, then indexes documents and runs asynchronous question answering and extraction workflows [GitHub, retrieved 2026]. Separately, a preliminary Frontiers paper reports that the ELISE parser, called Matsu, achieved a Normalized Edit Distance of 0.490463 on a global textual-content metric, which is useful as an existence proof of underlying document-parsing work but not, on its own, a commercial performance benchmark across customer deployments [Frontiers, 2025].
Partially corroborated -- Draws on TechCrunch, The Next Web, GitHub, and Frontiers, but several capability claims remain company-described rather than independently verified [TechCrunch, November 2024] [The Next Web, September 2026] [GitHub, retrieved 2026] [Frontiers, 2025].
Market Research
PUBLIC
The market matters now because life sciences teams are under pressure to adopt AI without breaking the evidentiary, validation, and audit requirements that govern regulatory and scientific work [TechCrunch, November 2024] [The Next Web, September 2026].
The available public record does not provide a named third-party TAM, SAM, or SOM estimate specific to Biolevate’s segment, so the market has to be framed from the workflow outward rather than from a headline market-size number. Biolevate began in medical writing and regulatory-document automation, then broadened its positioning to a wider life-sciences workflow layer spanning research, clinical development, regulatory submissions, drug discovery, and health-technology assessment [TechCrunch, November 2024] [Biolevate, September 2026]. That progression suggests the practical addressable market is not generic enterprise AI, but the subset of life sciences knowledge work where traceability, evidence linkage, and human review are mandatory operating conditions [The Next Web, September 2026] [FinancialContent, September 2026].
The demand signal surfaced in coverage is fairly consistent. TechCrunch’s 2024 reporting placed the initial wedge in helping medical writers keep pace with growing document volume around research and compliance workflows [TechCrunch, November 2024]. By September 2026, multiple outlets described Biolevate as serving more than ten enterprise customers in production, which does not size the market, but it does indicate that large regulated buyers are willing to move beyond pilots when the product is framed as governed workflow software rather than autonomous AI [The Next Web, September 2026] [FrenchWeb, September 2026].
The adjacent markets are easier to identify than the core market size. One is regulatory intelligence and change management, where Biolevate says it monitors fragmented regulatory frameworks and assesses the impact of regulatory shifts on a portfolio [Biolevate, retrieved 2026]. Another is enterprise knowledge management for scientific and clinical documents, reflected in product descriptions that include metadata extraction, document indexing, collaborative editing, version control, and connections to storage systems such as SharePoint, S3, Azure, GCS, SFTP, and local repositories [The AI Insider, November 2024] [GitHub, retrieved 2026]. A third substitute market is horizontal enterprise AI tooling, but Biolevate’s positioning argues that general-purpose copilots are not sufficient where every output must be tied back to controlled sources and approved by humans [The Next Web, September 2026] [Biolevate Careers, September 2026].
The regulatory and macro tailwinds are visible even without a formal market model. The company’s product narrative centers on auditable workflows, controlled sources, evidence-linked outputs, and governed human sign-off, which matches a broader enterprise shift toward AI systems that can survive internal quality review and external scrutiny in regulated sectors [TechCrunch, November 2024] [Biolevate Careers, September 2026] [FinancialContent, September 2026]. The other tailwind is organizational sprawl: scientific, healthcare, and regulatory information remains fragmented across unstructured documents and multiple repositories, which raises the value of software that can parse, structure, and retrieve evidence across systems instead of asking teams to change their core documentation habits [TechCrunch, November 2024] [GitHub, retrieved 2026].
| Market lens | What public sources support | Evidence quality |
|---|---|---|
| Core workflow market | Medical writing and regulatory-document automation as Biolevate's initial wedge [TechCrunch, November 2024] | YELLOW |
| Expanded adjacent market | Research, clinical development, regulatory submissions, drug discovery, and health-technology assessment [Biolevate, September 2026] | RED |
| Substitute market | Horizontal enterprise AI and knowledge-management tools for document-heavy teams [The AI Insider, November 2024] [GitHub, retrieved 2026] | YELLOW |
| Demand signal | More than 10 to 12 enterprise customers in production by September 2026 [The Next Web, September 2026] [FrenchWeb, September 2026] | YELLOW |
The table underscores the main limitation of the public evidence: the workflow demand is visible, but the market boundary is still defined mostly by product use cases and company positioning rather than by independent market-sizing research. That is still useful for investors, because it points to a category shaped less by broad AI spend and more by compliance-sensitive document and decision workflows inside life sciences.
Claim stands unchecked -- This section relies on a mix of independent press reporting and company-authored positioning, with no third-party market-sizing report confirmed.
Competition and Substitutes
MIXED Biolevate appears to be positioning less as a general-purpose AI vendor and more as a regulated-workflow layer for life sciences teams that need evidence-linked outputs, human sign-off, and auditability in scientific and regulatory work [TechCrunch, November 2024] [The Next Web, September 2026] [Biolevate Careers, September 2026].
The public record does not name direct competitors, which matters here because the category is broad and the company itself has stretched its positioning over time. The early wedge was medical-writing and regulatory-document automation through ELISE, aimed at medical writers handling research and compliance documents [TechCrunch, November 2024]. By September 2026, the company was describing a wider "AI Knowledge Platform" across research, clinical development, regulatory submissions, drug discovery, and health-technology assessment, with document ingestion across systems such as S3, Azure, GCS, SharePoint, SFTP, and local storage [Biolevate Careers, September 2026] [Biolevate, September 2026] [GitHub, retrieved 2026]. That puts Biolevate into competition with at least three classes of alternative, even if the sources stop short of naming them: incumbent document and quality systems already embedded in regulated organizations, narrower workflow tools focused on medical writing or regulatory affairs, and horizontal enterprise AI platforms that can be adapted for internal knowledge retrieval and extraction. The practical implication is that Biolevate is unlikely to win on model novelty alone. It has to win on workflow fit, validation controls, and implementation credibility inside regulated teams.
The current edge, to the extent public evidence supports one, is not distribution scale but product alignment with regulated decision trails. Multiple sources describe Biolevate's outputs as linked to supporting evidence and subject to human validation, and that is a more specific claim than generic enterprise AI positioning [The Next Web, September 2026] [Biolevate Careers, September 2026] [FinancialContent, September 2026]. The founding team's background as former Dataiku engineers and AI researchers also suggests technical fluency in enterprise data and model operations, which is relevant when buyers need systems that can connect to fragmented document estates rather than operate as a standalone chatbot [The Next Web, September 2026] [Tech.eu, September 2026]. Still, this edge looks perishable unless Biolevate converts product architecture into process entrenchment. Evidence-linking and governed workflows can be differentiated in an initial sale, but over an 18-month window similar controls can be replicated by better-capitalized software vendors if customers view them as features rather than a system of record.
The company's main exposure is breadth. Public materials show a move from a concrete initial use case, medical-writing and regulatory-document automation, toward a platform narrative spanning much of the life-sciences value chain [TechCrunch, November 2024] [Biolevate, September 2026]. That can expand deal size, but it also places Biolevate against adjacent substitutes with stronger incumbency in each budget line. A clinical-development buyer, a regulatory-operations buyer, and a drug-discovery buyer do not necessarily purchase from the same vendor or evaluate the same proof points. Biolevate's reported customer count, more than ten or more than 12 enterprises in production by September 2026 depending on source, is encouraging but still early relative to the number of functional domains the company now claims to serve [FrenchWeb, September 2026] [The Next Web, September 2026]. The company also does not appear, from the cited public record, to own a proprietary channel such as a mandated regulatory network or an exclusive data asset. Its Boston office and named partnerships with Sanofi, NVIDIA, and Microsoft may help credibility, but partnership visibility is not the same as owned distribution [The Next Web, September 2026] [Biolevate, September 2026].
The most plausible 18-month scenario is a split market rather than a single winner-take-most outcome. Biolevate is the likely winner if regulated buyers continue to prefer auditable, evidence-grade workflow products over broad horizontal copilots, because that preference fits its documented product story and early customer base [The Next Web, September 2026] [Finsmes, September 2026]. Biolevate is the likely loser if enterprise procurement consolidates AI spending into existing platform vendors and treats life-sciences-specific workflow tooling as an integration layer rather than a strategic system. In that case, the same breadth that helps the Series A narrative could make execution harder, especially if the company has to prove equal depth across regulatory, clinical, and research functions at once. The public evidence supports a credible opening position, but not yet a locked-in one.
Opportunity
Upside case
PUBLIC The prize here is not a better point tool for medical writers, but a chance to become the evidence and workflow layer that regulated life-sciences teams rely on when AI moves from experimentation into production across research, clinical, and regulatory work [TechCrunch, November 2024] [The Next Web, September 2026].
The headline opportunity is fairly specific. If Biolevate can extend its early wedge in medical writing and regulatory documentation into a broader system of record for evidence-linked AI workflows, it could become default operating infrastructure for knowledge-heavy work inside pharma, biotech, and medtech organizations [TechCrunch, November 2024] [Biolevate Careers, September 2026]. That outcome is still conditional, but it is not detached from the public record: the company has moved from a narrow document-automation story toward an enterprise "AI Knowledge Platform" position, says outputs are tied to supporting evidence and human sign-off, and had more than ten enterprise customers in production by September 2026 according to multiple publications [Biolevate Careers, September 2026] [The Next Web, September 2026] [FrenchWeb, September 2026]. In regulated markets, trust, traceability, and auditability are not feature polish. They are often the gating criteria for broader deployment.
The public evidence supports a few distinct paths to scale, each with a different catalyst.
| Scenario | What happens | Catalyst | Why it's plausible |
|---|---|---|---|
| Regulatory control layer | Biolevate becomes the system enterprises use to monitor regulatory change, assess impact, and update evidence-backed workflows across portfolios | A large pharmaceutical customer standardizes on the platform beyond medical writing into regulatory operations and submissions | The product started in regulatory-document automation and now emphasizes auditable workflows and regulatory monitoring for life-sciences teams [TechCrunch, November 2024] [Biolevate, retrieved 2026] [FinancialContent, September 2026] |
| Cross-functional life-sciences platform | The company expands from one buyer persona into research, clinical development, submissions, and health-technology assessment, raising ACV as more teams work from the same governed knowledge base | Successful U.S. expansion following the Boston office opening and broader enterprise adoption after the Series A | Biolevate is already positioning across the life-sciences value chain, and the September 2026 financing was paired with a Boston launch and a claim of more than 12 enterprise customers in production [Biolevate, September 2026] [The Next Web, September 2026] |
| Standard for evidence-grade enterprise AI | Biolevate wins because regulated organizations prefer AI outputs that are linked to source evidence, reviewed by humans, and governed through controlled workflows | Partnerships with large ecosystem players and named life-sciences enterprises turn product architecture into a de facto buying standard | Public materials and coverage repeatedly stress evidence-linked outputs, controlled sources, and human validation; Biolevate also names partnerships with Sanofi, NVIDIA, and Microsoft [The Next Web, September 2026] [FinancialContent, September 2026] [Biolevate, September 2026] |
The compounding dynamic is straightforward if the product works as advertised. A company that first lands on one painful workflow, such as medical writing or regulatory review, can then ingest more internal and external documents, build more governed workflows on top of that corpus, and make the platform harder to displace as traceable knowledge accumulates across teams [TechCrunch, November 2024] [GitHub, retrieved 2026]. Features such as metadata extraction, collaborative editing, version control, and connections into existing document stores matter here because they suggest Biolevate is trying to sit inside day-to-day operating systems rather than beside them [The AI Insider, November 2024] [GitHub, retrieved 2026]. The early sign that this flywheel may be starting is modest but real: by September 2026 the company had reached more than ten production enterprise customers and raised a Series A specifically to scale the platform into the U.S. market and across the value chain [FrenchWeb, September 2026] [The Next Web, September 2026] [Biolevate, September 2026].
The size of the win cannot be pinned to a clean public comparable from the provided source set, so the valuation frame has to stay conditional. If Biolevate were to become a standard enterprise platform for auditable AI in life sciences, the outcome could plausibly support a multi-billion-dollar enterprise value (scenario, not a forecast), because the company would be selling into large regulated customers on infrastructure-like rather than seat-tool economics [The Next Web, September 2026] [Biolevate Careers, September 2026]. What makes that more than a generic software upside story is the operating context: regulated organizations tend to keep systems that are embedded in controlled workflows, linked to evidence, and reviewed by compliance-sensitive users, which can widen contracts over time if initial deployments hold up [FinancialContent, September 2026] [The Next Web, September 2026].
Partially corroborated -- Built primarily from TechCrunch, The Next Web, FrenchWeb, Biolevate materials, and other public coverage; the upside case is grounded in reported product positioning and customer counts, but the broadest platform claims remain only partially corroborated.
Sources
Open sources
[Biolevate, September 2026] Biolevate Raises €30 Million Series A | https://www.biolevate.com/news/series-a-2026
[Biolevate, retrieved 2026] Biolevate | https://www.biolevate.com/
[Biolevate Careers, September 2026] Biolevate Careers | https://www.biolevate.com/pages/careers
[FinancialContent, September 2026] Biolevate Raises €30 Million Series A to Build the Trusted AI Operating Layer for Life Sciences | https://markets.financialcontent.com/stocks/article/bizwire-2026-9-22-biolevate-raises-30-million-series-a-to-build-the-trusted-ai-operating-layer-for-life-sciences
[FrenchWeb, September 2026] Avec 30 millions d'euros, BIOLEVATE veut faire de l'IA un outil de conformité pour les laboratoires | https://www.frenchweb.fr/avec-30-millions-deuros-biolevate-veut-faire-de-lia-un-outil-de-conformite-pour-les-laboratoires/463589
[Frontiers, 2025] MultiModal BioMedical and Clinical Document Parsing | https://www.frontiersin.org/journals/artificial-intelligence/articles/10.3389/frai.2025.1646617/full
[Finsmes, September 2026] Biolevate Raises €30M in Series A Funding | https://www.finsmes.com/2026/09/biolevate-raises-e30m-in-series-a-funding.html
[GitHub, retrieved 2026] biolevate/elise | https://github.com/biolevate/elise
[LinkedIn, retrieved 2026] joel Belafa - CEO @ Biolevate / AI unleashing Healthcare ... | https://fr.linkedin.com/in/joel-belafa-98139635/fr?trk=org-employees
[Sesamers, September 2026] Biolevate Raises €30M Series A to Build the AI Operating Layer for Life Sciences | https://sesamers.com/announcement/biolevate-raises-30m-series-a-to-build-the-ai-operating-layer-for-life-sciences/
[Tech.eu, September 2026] Biolevate lands €30M Series A to scale life sciences AI | https://tech.eu/2026/09/22/biolevate-lands-eur30m-series-a-to-scale-life-sciences-ai/
[TechCrunch, November 2024] Biolevate's raises €6M to helps medical writers keep up with the pace of new drugs | https://techcrunch.com/2024/11/25/biolevates-raises-e6m-to-helps-medical-writers-keep-up-with-the-pace-of-new-drugs/
[The AI Insider, November 2024] Biolevate Secures €6M to Improve Medical Writing With AI | https://theaiinsider.tech/2024/11/26/biolevate-secures-e6m-to-improve-medical-writing-with-ai/
[The Next Web, September 2026] Biolevate raises €30M Series A and opens Boston office for its life sciences AI | https://thenextweb.com/news/biolevate-raises-30m-series-a-boston
[Vestbee, November 2024] French healthcare startup Biolevate secures €6M led by EQT Ventures | https://www.vestbee.com/insights/articles/biolevate-secures-6-m
Articles about Biolevate
- Biolevate's AI Platform Convinced Sanofi and NVIDIA to Audit the Evidence — The Paris-based startup, founded by former Dataiku engineers, has raised €36 million to turn regulatory compliance into a traceable workflow.